0000950170-23-071631.txt : 20231219
0000950170-23-071631.hdr.sgml : 20231219
20231219175559
ACCESSION NUMBER: 0000950170-23-071631
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231215
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crowley John F
CENTRAL INDEX KEY: 0001400973
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 231498734
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 921-7600
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
ownership.xml
4
X0508
4
2023-12-15
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001400973
Crowley John F
47 HULFISH STREET
PRINCETON
NJ
08542
true
true
false
false
Executive Chairman
true
Common Stock
2023-12-15
4
S
false
6043
12.6619
D
877748
D
Common Stock
2023-12-18
4
A
false
34572
0.0
A
912320
D
Common Stock
64895
I
By Trust
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.51 to $12.83 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents a contingent right to receive common stock in the amount shown, for no consideration, due to the satisfaction of performance criteria underlying an award of performance based restricted stock units granted in 2021. Such units remain outstanding on the date hereof and will fully vest on December 31, 2023, subject to the Reporting Person's continued service with the Company.
All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
In addition to the reported transactions, Mr. Crowley also has approximately 845,000 options outstanding and exercisable at various strike prices.
/s/ Christian Formica, Attorney-in-Fact
2023-12-19